Numab Therapeutics Secures Additional $55 Million in Series C Funding to Advance Multi-Specific Antibody Therapies

Funding Amount:
Numab Therapeutics has raised an additional CHF 50 million ($55 million) in Series C funding, bringing the total Series C to CHF 180 million ($197 million)135.

Investors:
The funding round was co-led by Cormorant Asset Management, with participation from existing investors including Forbion, HBM Healthcare Investment, Novo Holdings, BVF Partners LP, Octagon Capital Advisors LP, RTW Investments, and funds managed by BlackRock135.

Use of Funds:
The proceeds will be used to accelerate and further advance Numab's pipeline of clinical and pre-clinical best-in-class and first-in-class multi-specific antibodies in inflammation and oncology135.

Technology Platforms:
Numab's proprietary λ-CapTM and MATCHTM technology platforms are key to its multi-specific antibody development, offering predictable stability, high yields, and robust manufacturability135.

Recent Milestones:
In 2024, Numab's spin-out Yellow Jersey Therapeutics was acquired by Johnson & Johnson for $1.25 billion, and Numab's lead asset NM32 entered Phase 1 trials in patients with solid tumors135.

Clinical Focus:
Numab is a clinical-stage biotechnology company focusing on developing multi-specific antibody-based immunotherapies for inflammation and cancer135.

Sources:

1. https://www.startupticker.ch/en/news/numab-raises-additional-chf50-million

3. https://tech.eu/2025/01/10/numab-therapeutics-raises-55m-for-antibody-based-immunotherapies/

5. https://www.globenewswire.com/news-release/2025/01/09/3007134/0/en/Numab-Therapeutics-Announces-Series-C-Extension-to-CHF-180-Million-Completing-Oversubscribed-CHF-50-Million-Financing.html